Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHB-104 + interferon beta-1a
- Development stage
- Unknown
- Lead developer
- RedHill Biopharma
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intramuscular, Subcutaneous
01
Overview
RHB-104 + interferon beta-1a is a combination therapy consisting of an oral antibiotic combination (RHB-104) and interferon beta-1a. RHB-104 contains three antibiotics (clarithromycin, clofazimine, and rifabutin) with potent intracellular, antimycobacterial and anti-inflammatory properties. This combination was studied as an add-on therapy for relapsing-remitting multiple sclerosis, based on the hypothesis that Mycobacterium avium subspecies paratuberculosis (MAP) infection may contribute to autoimmune diseases.
02
Targets
Beyond the preview
Go deeper on RHB-104 + interferon beta-1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RHB-104 + interferon beta-1a.